Document is current
Any future updates will be listed below
-
Authors
Dey, Rounak https://orcid.org/0000-0002-6540-8280
Zhou, Wei https://orcid.org/0000-0001-7719-0859
Kiiskinen, Tuomo https://orcid.org/0000-0002-6306-8227
Havulinna, Aki
Elliott, Amanda
Karjalainen, Juha
Kurki, Mitja
Qin, Ashley
,
Lee, Seunggeun https://orcid.org/0000-0002-8097-3878
Palotie, Aarno https://orcid.org/0000-0002-2527-5874
Neale, Benjamin https://orcid.org/0000-0003-1513-6077
Daly, Mark
Lin, Xihong https://orcid.org/0000-0001-7067-7752
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35-CA197449, P01-CA134294, U19-CA203654)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL113338)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 7 December 2021
Accepted: 22 August 2022
First Online: 16 September 2022
Competing interests
: B.M.N. is on the Scientific Advisory Board of Deep Genomics, and is a consultant for CAMP4 Therapeutics, Takeda, and Biogen. X.L. is a consultant to AbbVie Pharmaceuticals and Verily Life Sciences. M.J.D. is a founder of Maze Therapeutics and on the scientific advisory board of BC Platforms. The remaining authors declare no competing interests.
